

Achieving Coordinated Identification,  
Detection and Treatment of Heart Failure Summit

April 12th, Hyatt Regency Bethesda, MD

# Identification of Stage B Patients: Missed Opportunities

**Moderator:** Dr. Ileana Piña


**Panelists:** Dr. Mary Walsh  
Dr. Javed Butler  
Dr. Mark Drazner




# Achieving Coordinated Identification, Detection and Treatment of Heart Failure Summit

April 12th, Hyatt Regency Bethesda, MD

## Clinical Heart Failure Nomenclature




## Figure 2. Kaplan-Meier curves for survival.



# Achieving Coordinated Identification, Detection and Treatment of Heart Failure Summit

April 12th, Hyatt Regency Bethesda, MD

## Figure 1. ACC/AHA guidelines for the evaluation and management of chronic HF: evolution of HF and recommended therapy by stage.



# Achieving Coordinated Identification, Detection and Treatment of Heart Failure Summit

April 12th, Hyatt Regency Bethesda, MD



## Recommendations for Treatment of Stage B HF

Recommendations	COR	LOE
In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF	I	A
In patients with MI and reduced EF, evidence-based beta blockers should be used to prevent HF	I	B
In patients with MI, statins should be used to prevent HF	I	A
Blood pressure should be controlled to prevent symptomatic HF	I	A
ACE inhibitors should be used in all patients with a reduced EF to prevent HF	I	A
Beta blockers should be used in all patients with a reduced EF to prevent HF	I	C
An ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy who are at least 40 d post-MI, have an LVEF $\leq$ 30%, and on GDMT	IIa	B
Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF	III: Harm	C